Neuroblastoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Irinotecan, Temozolomide, Dinutuximab Variant #01 Partial | — | R 5 470 | 21d | — | — | ~17 | ~R 92 995 indirect | — |
Cyclophosphamide monotherapy Variant #01 | — | R 1 680 | 28d | — | ~15.8 mo | ~1 | ~R 1 680 PFS proxy · indirect | 1 |
Cyclophosphamide and Vincristine Variant #01 | — | R 425 | 14d | — | — | ~7 | ~R 2 972 indirect | — |
Naxitamab monotherapy Variant #01 Partial | — | — | 28d | — | — | ~5 | — | — |
4 of 4 regimens shown